{
    "2021-03-18": [
        [
            {
                "time": "2021-11-15",
                "original_text": "Don’t Lose Sight of Biogen’s Depression Drug. How It Could Send the Stock Much Higher.",
                "features": {
                    "keywords": [
                        "Biogen",
                        "depression drug",
                        "stock higher"
                    ],
                    "sentiment_score": 0.7,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "pharmaceuticals"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "false",
                    "ts_effect_direction": "none"
                }
            },
            {
                "time": "2021-11-16",
                "original_text": "Amid Variant Concern, US Government Stops Distribution Of Eli Lilly's Bamlanivimab In Three States",
                "features": {
                    "keywords": [
                        "variant concern",
                        "US government",
                        "Eli Lilly",
                        "Bamlanivimab",
                        "distribution stop"
                    ],
                    "sentiment_score": -0.6,
                    "policy_related": "true",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "healthcare",
                        "biotech"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "negative",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "negative"
                }
            },
            {
                "time": "2021-11-16",
                "original_text": "Lilly says its monoclonal antibody is no longer being ordered in 3 states due to variant concerns",
                "features": {
                    "keywords": [
                        "Lilly",
                        "monoclonal antibody",
                        "variant concerns",
                        "ordered"
                    ],
                    "sentiment_score": -0.5,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "healthcare",
                        "biotech"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "negative",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "negative"
                }
            }
        ]
    ]
}